By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Ben Trotman, diagnosed with terminal glioblastoma in 2022, experienced a complete remission after receiving ipilimumab before ...

New RNA vaccine shows promise in turning resistant tumors into immunotherapy targets. Study offers hope for more effective, ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year.

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

The 81,000-square-foot facility will enhance the health system's cancer care offerings in the UK, with completion expected in ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

"If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence," said lead ...